Enliven Therapeutics slips on $250 mln equity offering

Enliven Therapeutics

11/06/2026 21:22

** Enliven Therapeutics' ELVN.O down 2.7% at $39.28 post-market after equity offering news
** Biopharma kicks off $250 mln offering comprising stock and pre-funded warrants 
** Jefferies, Goldman Sachs, Morgan Stanley and Barclays joint bookrunners
** ELVN stock finished up 9.1% at $40.36 on Thurs after its leukemia drug, ELVN-001, showed encouraging early-stage results
** Boulder, Colorado-based firm has 60.9 mln shares outstanding for $2.5 bln market cap
** At close, stock up 162% YTD
** All 12 analysts rate the stock "strong buy" or "buy"; median PT $59.50, according to LSEG data
     

(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))